Oral Cancer Drugs Deserve Parity
Add to that mix the proliferation of high-deductible health plans, which place more of the cost burden for medical care on enrollees, and it's no wonder sick people are forced to make tough choices.
While no one thinks it's helpful for a patient to skip medications or not comply with a treatment regimen, real solutions to this problem are lacking. With oral cancer drugs accounting for 25% to 35% of the drugs in the cancer drug pipeline this is a parity issue and it's not going away.
I reached out to several health plans to explain why benefits for oral cancer drugs are paid from pharmacy while injectable cancer drugs are part of medical benefits. The silence was deafening; I didn't even get the classic "no comment." So I turned to Susan Pisano, a spokesperson for America's Health Insurance Plans, the advocacy group for health plans. Her explanation was simple: "It's because of the way the drugs are administered. Traditionally, injectables are a medical benefit."
She said there has been discussion within the health plan industry regarding shifting oral cancer drugs to the medical benefit but not much has happened on that front. She added that the assumption that the shift would automatically lower the cost of oral cancer drugs wasn't always valid. Without being too specific, she said, "there are instances where a member would end up paying more for their drugs."
Pisano noted that health plans have taken many steps to help hold down drug costs for their members, including bulk purchasing, but at the end of the day "[you] have to wonder why a cancer drug would cost $20,000."
- CMS to Speak with ICD-10 Backers Tuesday
- Feds Stonewall ICD-10 Summit
- Managed Care Contract Negotiations Morph Under PPACA
- Cyberattack Drill Exposes Healthcare's Vulnerabilities
- NY Abolishes Written Practice Agreement for NPs
- Hospital Groups Back NQF Report on Patient Sociodemographics
- Physician Payment Data is Where the Action Is
- Why Cedars-Sinai Screens All Inpatient Adults for Depression
- Blum Latest Leader to Exit HHS
- 3 Patient Experience Improvements Every Marketer Can Make